AMISH : Aprovel for Management of Isolated Systolic Hypertension

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00264212
Recruitment Status : Completed
First Posted : December 12, 2005
Last Update Posted : December 21, 2007
Bristol-Myers Squibb
Information provided by:

December 9, 2005
December 12, 2005
December 21, 2007
August 2004
Not Provided
Change from baseline in office seated SBP at week 12
Not Provided
Complete list of historical versions of study NCT00264212 on Archive Site
At 4, 8 and 12 weeks: Number of responders and normalized, Change from baseline in pulse pressure (SBP-DBP), Change from baseline in standing SBP, Safety : Change in standing SBP/DBP, incidence of orthostatic hypotension, adverse events
Not Provided
Not Provided
Not Provided
AMISH : Aprovel for Management of Isolated Systolic Hypertension
A Multicentre Prospective Randomized Open-Label 12-Week Study With Blinded Evaluation Comparing the Efficacy and Safety of Irbesartan and Irbesartan-Hydrochlorothiazide Fixed Combination With Amlodipine and Amlodipine Plus Hydrochlorothiazide in Elderly Patients With Isolated Systolic Hypertension
To compare the antihypertensive efficacy and tolerability of irbesartan and irbesartan-hydrochlorothiazide fixed combination therapy with amlodipine and amlodipine plus hydrochlorothiazide in the treatment of isolated systolic hypertension.
Not Provided
Phase 4
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Drug: irbesartan and irbesartan-hydrochlorothiazide
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
Not Provided
Not Provided
Not Provided

Main criteria are listed hereafter:

Inclusion Criteria:

  • at Screening

    • Outpatients
    • With newly diagnosed and untreated OR previously diagnosed, treated and uncontrolled Isolated Systolic Hypertension defined as:

      • seated Systolic Blood Pressure (SBP) ≥ 160mmHg and < 220 mmHg [160-220[
      • AND seated Diastolic Blood Pressure (DBP)< 90 mmHg
  • at Randomization

    • Having completed the 2 to 4-week wash-out/placebo run-in phase
    • Still eligible for Blood Pressure
    • seated SBP ≥ 160mmHg and < 220 mmHg [160-220[
    • AND seated DBP < 90 mmHg.

Exclusion Criteria (at Screening):

  • Participation in a clinical trial within the previous 3 months
  • Patients with a history of irbesartan, amlodipine, or hydrochlorothiazide sensitivity defined as irbesartan, amlodipine, or hydrochlorothiazide discontinuation due to medically significant adverse effects
  • Patients currently or previously treated with Angiotensin II Receptor Blocker (irbesartan, losartan, candesartan, valsartan, telmisartan, etc.) or dihydropiridine Calcium Channel Blocker (amlodipine, nicardipine, felodipine, nifedipine, etc.) AND not responding despite maximum tolerated dose
  • Known or suspected secondary hypertension (e.g., coarctation of aorta, renovascular stenosis, etc.)
  • Known single functional kidney
  • History of recent myocardial infarction, coronary artery bypass graft surgery or percutaneous transluminal coronary angioplasty, or cerebrovascular accident (Transient Ischaemic Attack, stroke) within the last 6 months of study entry
  • Patients with known gastrointestinal, renal, hepatic, endocrine, cardiovascular, pulmonary, immunological or hematological disease which in the opinion of the investigator is active or uncontrolled
  • Patients with significant renal (clearance of creatinine < 30 mL/mn), hepatic or cardiac insufficiency, or known valvular heart disease
  • Serum potassium < 3.5 mmol/L (mEq/L) or > 5.5 mmol/L (mEq/L)
  • Presence of clinically significant ventricular or supraventricular arrhythmias, or second or third degree atrioventricular block, or QTc prolongation (Bazett > 450 msec.) on the ECG
  • Pregnancy or lactation. Women of child bearing potential (not post-menopausal) should be using a reliable contraceptive method

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Sexes Eligible for Study: All
60 Years to 90 Years   (Adult, Older Adult)
Contact information is only displayed when the study is recruiting subjects
Chile,   China,   Indonesia,   Korea, Republic of,   Mexico,   Philippines,   Taiwan,   Thailand
Not Provided
Not Provided
Not Provided
Not Provided
Bristol-Myers Squibb
Study Director: Pascale BLONDIN, MD Sanofi
December 2007

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP